Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder

Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder

Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease prog...

Full description

Bibliographic Details
Main Author: Jallad, Samer
Published: University of Brighton 2015
Subjects:
610
A000 Medicine
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922
id ndltd-bl.uk-oai-ethos.bl.uk-678922
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-6789222018-10-16T03:23:51ZBiomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladderJallad, Samer2015Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease progression. The alternative, radical cystectomy, has major risks with high morbidity and mortality. The ability to predict the response to BCG treatment would be a useful tool in the selection of appropriate treatment modalities. This study investigated a variety of detectable immune responses in blood and urine to establish if there were differences between responders and non-responders to BCG treatment. We evaluated whether there were detectable immunological differences in blood or urine that could explain or predict outcome.610A000 MedicineUniversity of Brightonhttps://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922https://research.brighton.ac.uk/en/studentTheses/9dab009b-4eaa-4f3a-a14c-a941f3948ccbElectronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 610
A000 Medicine
spellingShingle 610
A000 Medicine
Jallad, Samer
Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
description Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease progression. The alternative, radical cystectomy, has major risks with high morbidity and mortality. The ability to predict the response to BCG treatment would be a useful tool in the selection of appropriate treatment modalities. This study investigated a variety of detectable immune responses in blood and urine to establish if there were differences between responders and non-responders to BCG treatment. We evaluated whether there were detectable immunological differences in blood or urine that could explain or predict outcome.
author Jallad, Samer
author_facet Jallad, Samer
author_sort Jallad, Samer
title Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
title_short Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
title_full Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
title_fullStr Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
title_full_unstemmed Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
title_sort biomedical markers of response to intravesical bcg treatment in high-grade non-muscle invasive (pta and pt1) transitional cell carcinoma of the bladder
publisher University of Brighton
publishDate 2015
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922
work_keys_str_mv AT jalladsamer biomedicalmarkersofresponsetointravesicalbcgtreatmentinhighgradenonmuscleinvasiveptaandpt1transitionalcellcarcinomaofthebladder
_version_ 1718774214951960576

Similar Items